0.75 / AMA PRA Category 1 Credit(s)TM 0.75 / CE for Nurses (0.30 pharmacotherapeutic contact hours)
Jointly provided by American Academy of CME, Inc. and CME Matters, Inc.
Supported by Incyte Corporation
One of three primary Ph-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV) is a clonal disorder characterized by unwarranted production of red blood cells. Presently, the majority of patients are diagnosed only by chance or following a thrombotic event, representing a significant lost opportunity to start treatment early in the course of the disease. Of those patients with PV, approximately 6% will progress to develop myelofibrosis (MF), another MPN that carries a significantly reduced average overall survival compared to PV. This activity utilizes a unique, visually-oriented, self-paced and animated infographic format covering the diagnosis and treatment of patients with PV and MF.
The target audience for this initiative includes hematologists, oncologists, hematology/oncology nurses, emergency room physicians and nurses, or anyone in the position to diagnose and/or treat patients with PV and MF.
After completing this activity, the participant should be better able to:
Identify the most common presenting characteristics of patients with PV prior to diagnosis
Weigh the benefits and drawbacks of aggressive front-line treatment of PV
Analyze the potential effectiveness and side effect profiles for second-line treatment options used in patients with PV who are either intolerant or refractory to hydroxyurea
Identify risk factors for progression to post-PV MF, as well as prognostic variables that may impact overall survival once progression occurs
Discuss the clinical effectiveness and side effect profile of approved and investigational agents used to treat MF
Conflict Of Interest Disclosure Policy
All faculty, planners and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
Ross Levine, MD Member, Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York, NY
Dr. Levine has affiliations with with Cell Therapeutics Biopharma, Incyte Corporation, Novartis (Advisory Boards), Incyte Corporation and Novartis (Grant Recipient).
Michael Savona, MD Associate Professor of Medicine Director, Hematology Early Therapeutics Program Vanderbilt-Ingram Cancer Center Nashville, TN
Dr. Savona has affiliations with Amgen, Ariad, Baxalta, Celgene, Gilead, Incyte Corporation, Karyopharm, Novartis (Advisory Board), Karyopharm, Bristol-Myers Squibb (Consultant), Karyopharm (Shareholder), Astex, Sunesis, Incyte Corporation,Takeda, and TG Therapeutics (Grant Recipient).
Accredited Provider Disclosure
Cathy Pagano, CHCP, and Scott Kober, MBA, CHCP, (CME Matters LLC), and John JD Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD—Lead Nurse Planner (American Academy of CME, Inc.) have no relevant financial relationships specific to the subject matter within the past 12 months.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., (Academy) and CME Matters LLC. The Academy is accredited by the ACCME to provide continuing medical education for physicians.
The Academy designates this activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
American Academy of CME, Inc. designates this educational activity for 0.75 contact hours (0.30 pharmacotherapeutic contact hours).
Disclosure of Unlabeled Use
This activity will not review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, CME Matters or American Nurses Credentialing Center’s Commission on Accreditation. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test (achieving a passing score of 70%) and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.